Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with ...

(RTTNews) - Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

CSF pharmacokinetics of high-dose pulsatile tyrosine kinase therapy in brain cancer patients. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a ...

Survival effect of bi-shRNAfurin/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response. This is an ASCO Meeting Abstract from the 2014 ASCO Annual ...